Immunosuppression in clinical practice Approaches to individualized therapy

被引：3

作者：

Chan, Andrew ^{[1
]}

Stueve, Olaf ^{[2
]}

von Ahsen, Nicolas ^{[3
]}

机构：

[1] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany

[2] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dept Neurol, VA N Texas Hlth Care Syst,Neurol Sect,Med Serv, Dallas, TX 75390 USA

[3] Univ Gottingen, Dept Clin Chem, Fac Med, Gottingen, Germany

来源：

JOURNAL OF NEUROLOGY | 2008年 / 255卷 / Suppl 6期

关键词：

mitoxantrone; azathioprine; cyclophosphamide; methotrexate; pharmacogenetics;

D O I：

10.1007/s00415-008-6005-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.

引用

页码：22 / 27

页数：6

共 46 条

[1]

AIMARD G, 1978, REV NEUROL, V134, P215

[2] Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane [J].

Bernitsas, E ;

Wei, W ;

Mikol, DD .

ANNALS OF NEUROLOGY, 2006, 59 (01) :206-209

[3] Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician [J].

Boster, Aaron ;

Edon, Gilles ;

Frohman, Elliott ;

Javed, Adii ;

Stuve, Olaf ;

Tselis, Alexandros ;

Weiner, Howard ;

Weinstock-Guttman, Bianca ;

Khan, Omar .

LANCET NEUROLOGY, 2008, 7 (02) :173-183

[4] Azathioprine for multiple sclerosis [J].

Casetta, I ;

Iuliano, G. ;

Filippini, G. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (04)

[5] Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients [J].

Chan, A ;

Weilbach, FX ;

Toyka, KV ;

Gold, R .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 139 (01) :152-158

[6]

Chan A, 2007, NEUROLOGY, V68, pA312

[7] Avonex Combination Trial in relapsing-remitting MS: rationale, design and baseline data [J].

Cohen, J. A. ;

Calabresi, P. A. ;

Chakraborty, S. ;

Edwards, K. R. ;

Eickenhorst, T. ;

Felton, W. L., III ;

Fisher, E. ;

Fox, R. J. ;

Goodman, A. D. ;

Hara-Cleaver, C. ;

Hutton, G. J. ;

Imrey, P. B. ;

Ivancic, D. M. ;

Mandell, B. F. ;

Perryman, J. E. ;

Scott, T. F. ;

Skaramagas, T. T. ;

Zhang, H. .

MULTIPLE SCLEROSIS, 2008, 14 (03) :370-382

[8] Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-β [J].

Correale, J ;

Rush, C ;

Amengual, A ;

Goicochea, MT .

JOURNAL OF NEUROIMMUNOLOGY, 2005, 162 (1-2) :173-183

[9] Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis [J].

Debouverie, M ;

Vandenberghe, N ;

Morrissey, SP ;

Anxionnat, R ;

Pittion-Vouyovitch, S ;

Vespignani, H ;

Edan, G .

MULTIPLE SCLEROSIS, 2004, 10 (04) :407-412

[10] Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis [J].

Dervieux, Thierry ;

Greenstein, Neal ;

Kremer, Joel .

ARTHRITIS AND RHEUMATISM, 2006, 54 (10) :3095-3103

← 1 2 3 4 5 →